Thomas S. C. Ng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Thomas S. C. Ng has a total of 267 co-authors. Here are the top co-authors by number of shared publications:
- Miles A. Miller
Center for Systems Biology, Massachusetts General Hospital Research Institute, Boston, Massachusetts
52 shared publications - Ralph Weissleder
Massachusetts General Hospital
50 shared publications - Ran Li
Translational Pharmacokinetics and Pharmacodynamics, Genentech Inc, South San Francisco, USA
48 shared publications - Huiyu Hu
Department of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China
47 shared publications - Dylan Matvey
Center for Systems Biology, Massachusetts General Hospital Research Institute, Boston, Massachusetts
46 shared publications - Ella Scott
Center for Systems Biology Massachusetts General Hospital 185 Cambridge St, CPZN 5206 Boston MA 02114 USA
46 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (63) , e77301
Multiplexed Profiling of Individual Extracellular Vesicles Reveals Lung Cancer‐Associated Protein Signatures
Lung cancer is frequently diagnosed after curative treatment windows have narrowed, creating a need for minimally invasive biomarkers that report tumor development at earlier stages. Extracellular vesicles (EVs) are promising analytical targets because they carry molecular cargo from their originating cells, but tumor‐associated EV signals can be rare in blood and obscured in bulk measurements. Here, we present Cygnus ( Cy clic‐imaging g ateway to n anovesicles u nderlying s ignature), an end‐to‐end workflow that integrates cyclic immunofluorescence imaging with multiscale analysis of individual EVs. Cygnus preserves vesicle‐level measurements, quantifies marker co‐expression, resolves EV subpopulations, and summarizes single‐vesicle phenotypes into sample‐level profiles. In a genetically engineered mouse model of lung adenocarcinoma, Cygnus revealed dynamic changes in EV protein composition and identified an EpCAM‐ and/or CTSH‐positive EV subpopulation before tumors were detectable by radiography. In a pilot clinical cohort ( n = 35), plasma EV profiling showed lung cancer‐associated marker patterns compared with non‐cancer controls and nominated a CTSH/PDL1/MET marker combination for future validation. These findings support multiplexed individual‐EV profiling as a strategy for defining candidate lung cancer‐associated EV signatures and position Cygnus as an integrated workflow for translating vesicle‐level heterogeneity into sample‐level EV profiles.
- 25 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (63) , e77301
Open AccessMultiplexed Profiling of Individual Extracellular Vesicles Reveals Lung Cancer‐Associated Protein Signatures
Lung cancer is frequently diagnosed after curative treatment windows have narrowed, creating a need for minimally invasive biomarkers that report tumor development at earlier stages. Extracellular vesicles (EVs) are promising analytical targets because they carry molecular cargo from their originating cells, but tumor‐associated EV signals can be rare in blood and obscured in bulk measurements. Here, we present Cygnus ( Cy clic‐imaging g ateway to n anovesicles u nderlying s ignature), an end‐to‐end workflow that integrates cyclic immunofluorescence imaging with multiscale analysis of individual EVs. Cygnus preserves vesicle‐level measurements, quantifies marker co‐expression, resolves EV subpopulations, and summarizes single‐vesicle phenotypes into sample‐level profiles. In a genetically engineered mouse model of lung adenocarcinoma, Cygnus revealed dynamic changes in EV protein composition and identified an EpCAM‐ and/or CTSH‐positive EV subpopulation before tumors were detectable by radiography. In a pilot clinical cohort ( n = 35), plasma EV profiling showed lung cancer‐associated marker patterns compared with non‐cancer controls and nominated a CTSH/PDL1/MET marker combination for future validation. These findings support multiplexed individual‐EV profiling as a strategy for defining candidate lung cancer‐associated EV signatures and position Cygnus as an integrated workflow for translating vesicle‐level heterogeneity into sample‐level EV profiles.
- 1 April 2026
- Published by Springer Nature
- p. 87-102
Quantitative Assessment in Nuclear Cardiology
- 1 April 2026
- Published by Springer Nature
- p. 463-542
Quantitative Thoracic Imaging with Nuclear Medicine
- 1 April 2026
- Published by Springer Nature
- p. 463-542
Quantitative Thoracic Imaging with Nuclear Medicine
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
IGF1R inhibition augments macropinocytosis and is blocked by IGF1
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
IGF1R inhibition augments macropinocytosis and is blocked by IGF1
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
Pharmacologic screening, over-representation analysis, and gene expression of macropinocytosis screen hits
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
Pharmacologic screening, over-representation analysis, and gene expression of macropinocytosis screen hits
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
IGF1R and IGF1 expression in four individual ATC patients, and IGF1 expression in myeloid cell subsets
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
IGF1R and IGF1 expression in four individual ATC patients, and IGF1 expression in myeloid cell subsets
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
Assessment of albumin-bound chemotherapy efficacy and toxicity
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
Assessment of albumin-bound chemotherapy efficacy and toxicity
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
MAPK pathway kinase inhibitors show little effect on albumin uptake in non-tumor tissues, and lectin and dextran uptakes in tumor tissues
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
MAPK pathway kinase inhibitors show little effect on albumin uptake in non-tumor tissues, and lectin and dextran uptakes in tumor tissues
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
Albumin uptake is dependent on macropinocytosis in ATC
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
Albumin uptake is dependent on macropinocytosis in ATC
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
Biological and chemical reagents and their sources
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response
Biological and chemical reagents and their sources